FDA-cleared profile

HS40 Diagnostic Ultrasound System

Samsung Medison Co., Ltd. · Ultrasound · FDA-cleared (510(k))

Authorized purpose: HS40 is a general-purpose diagnostic ultrasound system for imaging and analysis of body fluids in fetal and obstetric, abdominal, gynecologic, pediatric, small-organ, cephalic, cardiac, vascular, musculoskeletal, and urologic applications by trained healthcare professionals.

Clinical role
Diagnostic ultrasound acquisition, measurement, analysis, reporting, and release-specific assistance under professional control.
Images and patients
Ultrasound · Fetus; abdomen; pelvis; small organs; head; heart; peripheral vessels; musculoskeletal; and urologic organs
Key limitation
Keep in mind: Supported probes, host devices, populations, applications, and optional functions vary by exact release; image-quality assessment and clinical interpretation remain with qualified professionals.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: HS40 is a general-purpose diagnostic ultrasound system for imaging and analysis of body fluids in fetal and obstetric, abdominal, gynecologic, pediatric, small-organ, cephalic, cardiac, vascular, musculoskeletal, and urologic applications by trained healthcare professionals.
  • Which images or clinical context are in scope?Modality: Ultrasound Anatomy or clinical context: Fetus; abdomen; pelvis; small organs; head; heart; peripheral vessels; musculoskeletal; and urologic organs Input: Live or imported ultrasound data from supported probes, host systems, patient studies, and labeled applications.
  • Who uses it?Intended users: Qualified physicians, sonographers, and other trained ultrasound professionals.
  • What does the software produce?Output: Ultrasound images, measurements, calculations, overlays, and reports for professional review.
  • What is its most important limitation?Key limitation: Supported probes, host devices, populations, applications, and optional functions vary by exact release; image-quality assessment and clinical interpretation remain with qualified professionals.

Clinical takeaway. Clinical role: HS40 is a general-purpose diagnostic ultrasound system for imaging and analysis of body fluids in fetal and obstetric, abdominal, gynecologic, pediatric, small-organ, cephalic, cardiac, vascular, musculoskeletal, and urologic applications by trained healthcare professionals.

Evidence takeaway. Evidence from the reviewed source record: The exact FDA document reports non-clinical acoustic output, biocompatibility, software, cleaning and safety testing, and states clinical studies were not required. NerveTrack AI validation on 2,146 images from 18 subjects reported average accuracy (%) 91.7 (95% CI 89.5 to 93.9). A deep learning uterus segmentation algorithm, validated on 450 sagittal and 150 transverse uterus images from three hospitals, had average dice-scores of 96% (uterus) and 92% (endometrium). Results are as reported in the FDA submission, not independent validation.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
HS40 is a general-purpose diagnostic ultrasound system for imaging and analysis of body fluids in fetal and obstetric, abdominal, gynecologic, pediatric, small-organ, cephalic, cardiac, vascular, musculoskeletal, and urologic applications by trained healthcare professionals.
  • Exact FDA submission
  • Checked 2026-09-04
Workflow role
Diagnostic ultrasound acquisition, measurement, analysis, reporting, and release-specific assistance under professional control.
  • Exact FDA submission
  • Checked 2026-09-04
Required input
Live or imported ultrasound data from supported probes, host systems, patient studies, and labeled applications.
  • Exact FDA submission
  • Checked 2026-09-04
Output and clinician action
Ultrasound images, measurements, calculations, overlays, and reports for professional review.
  • Exact FDA submission
  • Checked 2026-09-04
Care setting
Hospitals, clinics, offices, operating rooms, and other medical settings within the labeled applications.
  • Exact FDA submission
  • Checked 2026-09-04
Intended users
Qualified physicians, sonographers, and other trained ultrasound professionals.
  • Exact FDA submission
  • Checked 2026-09-04
Limitations
Supported probes, host devices, populations, applications, and optional functions vary by exact release; image-quality assessment and clinical interpretation remain with qualified professionals.
  • Exact FDA submission
  • Checked 2026-09-04
Evidence summary
The exact FDA document reports non-clinical acoustic output, biocompatibility, software, cleaning and safety testing, and states clinical studies were not required. NerveTrack AI validation on 2,146 images from 18 subjects reported average accuracy (%) 91.7 (95% CI 89.5 to 93.9). A deep learning uterus segmentation algorithm, validated on 450 sagittal and 150 transverse uterus images from three hospitals, had average dice-scores of 96% (uterus) and 92% (endometrium). Results are as reported in the FDA submission, not independent validation.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "The device has been evaluated for acoustic output, biocompatibility, software function, cleaning and disinfection effectiveness as well as thermal, electrical, electromagnetic and mechanical safety" … "The subject of this premarket submission, HS40, dose not require clinical studies to support substantial equivalence.". Read from the exact FDA decision document on 2026-11-14.

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
The exact FDA document reports non-clinical acoustic output, biocompatibility, software, cleaning and safety testing, and states clinical studies were not required. NerveTrack AI validation on 2,146 images from 18 subjects reported average accuracy (%) 91.7 (95% CI 89.5 to 93.9). A deep learning uterus segmentation algorithm, validated on 450 sagittal and 150 transverse uterus images from three hospitals, had average dice-scores of 96% (uterus) and 92% (endometrium). Results are as reported in the FDA submission, not independent validation.
  • FDA source
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "The device has been evaluated for acoustic output, biocompatibility, software function, cleaning and disinfection effectiveness as well as thermal, electrical, electromagnetic and mechanical safety" … "The subject of this premarket submission, HS40, dose not require clinical studies to support substantial equivalence.". Read from the exact FDA decision document on 2026-11-14.

Reported sensitivity
Not applicable
  • Not applicable
  • Not applicable
  • Checked 2026-09-04

Sensitivity is not promoted as a product-wide endpoint for this device or software function. Compare only an exact endpoint, threshold, population, version, and source if later verified.

Reported specificity
Not applicable
  • Not applicable
  • Not applicable
  • Checked 2026-09-04

Specificity is not promoted as a product-wide endpoint for this device or software function. Compare only an exact endpoint, threshold, population, version, and source if later verified.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

K221599 FDA evidence package for HS40 Diagnostic Ultrasound System

  • DesignFDA 510(k) substantial-equivalence decision evidence and product verification described in the exact submission.
  • PopulationFetus; abdomen; pelvis; small organs; head; heart; peripheral vessels; musculoskeletal; and urologic organs
  • Scopeexact submission
  • Tested versionHS40 Diagnostic Ultrasound System configuration described in K221599
  • IndependenceSponsor or vendor study

K221599

Manufacturer evidence submitted for the exact FDA decision. It is not independent clinical validation, and local technical, clinical, privacy, security, and workflow acceptance remains necessary.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The 2026-09-02 openFDA device-recall snapshot contained no record matched to K221599 by exact native submission identifier. This does not exclude product-family, later, or adverse-event information.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-04

Exact-identifier review does not prove absence of all product-family safety signals.

Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not publicly available: Reviewed sources do not publish an exact-product procurement price with a stated offer scope.

Reimbursement

Reimbursement
No separate named-product Medicare payment was identified in the reviewed CMS coverage material. Evaluate the product within the applicable imaging, procedural, or surgical service line and verify payer, site-of-service, and coding assumptions independently.
  • Service-level, not product-specific
  • Checked 2026-09-04

No product-specific code

No separate named-product payment identified in reviewed public material

Centers for Medicare & Medicaid Services · United States

This is not a product-specific reimbursement determination. Build a local total-cost and value model and verify payer, site-of-service, coding, and coverage assumptions independently.

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: Live or imported ultrasound data from supported probes, host systems, patient studies, and labeled applications.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-04 · FDA 510(k) decision material K221599: HS40 Diagnostic Ultrasound System

  2. Routing

    Unresolved route: Not established for the exact route.

    Scope: Exact FDA submission. The exact public FDA decision material does not establish a complete integration contract. Confirm DICOM, worklist, identity, interfaces, exports, routing, audit behavior, and downtime locally.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-04 ·

  3. AI processing

    Source context, not route validation: The exact FDA package describes the HS40 as a general purpose, mobile, software controlled diagnostic ultrasound system to which the AI-based UterineAssist feature was added. Current hosting, data flow, and commercial configuration require vendor confirmation.

    Scope: Exact FDA submission. Packet wording: "The HS40 is a general purpose, mobile, software controlled, diagnostic ultrasound system." … "The proposed HS40 has added the UterineAssist based on AI already cleared in the predicate devce V8(K211945)". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-11-14 · FDA 510(k) decision material K221599: HS40 Diagnostic Ultrasound System

  4. Returned objects

    Source context, not route validation: Ultrasound images, measurements, calculations, overlays, and reports for professional review.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-04 · FDA 510(k) decision material K221599: HS40 Diagnostic Ultrasound System

  5. Viewer/worklist/report

    Unresolved route: Ultrasound images, measurements, calculations, overlays, and reports for professional review.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-04 · FDA 510(k) decision material K221599: HS40 Diagnostic Ultrasound System

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
The exact FDA package describes the HS40 as a general purpose, mobile, software controlled diagnostic ultrasound system to which the AI-based UterineAssist feature was added. Current hosting, data flow, and commercial configuration require vendor confirmation.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "The HS40 is a general purpose, mobile, software controlled, diagnostic ultrasound system." … "The proposed HS40 has added the UterineAssist based on AI already cleared in the predicate devce V8(K211945)". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

Security
Samsung Healthcare USA's security advisories page, published under Boston Imaging (a Samsung company), posts vulnerability impact analyses and patch process statements for Samsung computed tomography, ultrasound and digital radiography modalities (including Log4j, Urgent11, BlueKeep and WannaCry analyses).
  • Vendor-wide
  • Checked 2026-10-26

Vendor statement, not an attestation. Identity bridge: owning-domain press releases on usa.samsunghealthcare.com state that Boston Imaging is Samsung Medison's U.S. medical imaging business (unified as Samsung HME America, March 2026) and that Samsung Medison is an affiliate of Samsung Electronics. Corporate program statement; exact-release scope is not established.

Training
Only qualified physicians, sonographers, and other trained ultrasound professionals should operate or interpret the product. Local onboarding should cover the exact release, supported population, limitations, failure examples, escalation, downtime, and competency documentation.
  • Exact FDA submission
  • Checked 2026-09-04
Monitoring
Monitor K221599 by exact hardware, software, model, and algorithm version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: Supported probes, host devices, populations, applications, and optional functions vary by exact release; image-quality assessment and clinical interpretation remain with qualified professionals.
  • Exact FDA submission
  • Checked 2026-09-04

Monitoring guidance is buyer-facing implementation guidance derived from the exact cleared scope; it is not a claim that the FDA package provides a live monitoring service.

Release and scope verification

Map installed model, build, options, population, anatomy, inputs, outputs, and enabled functions to K221599 before acceptance.

exact submission · checked 2026-09-04

Later product-family features are not evidence that this cleared release includes them.

Deployment boundary

The exact public deployment topology remains incomplete; establish hosting responsibility, data flow, availability, upgrade, service, and downtime boundaries locally.

exact submission · checked 2026-09-04

FDA-described deployment boundaries do not establish current hosting contracts, security controls, uptime, or local qualification.

Interoperability acceptance

The exact public integration contract remains incomplete; establish and test supported input, output, identity, routing, archive, and downtime behavior locally.

exact submission · checked 2026-09-04

Test representative identifiers, orientation, geometry, measurements, units, routing, failure handling, and round trips locally.

Clinical acceptance

Use a signed local test set for the supported population and workflow. Include common and difficult cases, exclusions, acquisition variation, failed or low-quality inputs, reviewer overrides, and downstream effects. Supported probes, host devices, populations, applications, and optional functions vary by exact release; image-quality assessment and clinical interpretation remain with qualified professionals.

exact submission · checked 2026-09-04

Define stop-use, escalation, rollback, and revalidation triggers before production use.

Economic evaluation

Model capital and recurring cost against net staff time after review, throughput, repeat imaging or rework, room time, consumables, infrastructure, training, service, downtime, upgrade, and replacement costs.

product family · checked 2026-09-04

No exact-product price was found in the reviewed public material; productivity or value claims require local evidence.

Lifecycle monitoring

Monitor K221599 by exact hardware, software, model, and algorithm version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: Supported probes, host devices, populations, applications, and optional functions vary by exact release; image-quality assessment and clinical interpretation remain with qualified professionals.

exact submission · checked 2026-09-04

Revalidate after material software, hardware, model, protocol, interface, or clinical-policy changes. general-purpose diagnostic ultrasound system limits remain submission-specific.

Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K221599
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
Ultrasound
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-04
Anatomy
Fetus; abdomen; pelvis; small organs; head; heart; peripheral vessels; musculoskeletal; and urologic organs
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-04
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2022-08-22
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Human reviewedStatus
2026-09-20Last searched
27Fields reviewed
12Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, fda decision material, peer reviewed literature, clinical trial registry, reimbursement policy, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not publicly available - checked 2026-09-04 - Exact FDA submission

    No public list price for the exact cleared configuration was found. Obtain a written quote separating hardware or license basis, implementation, interfaces, infrastructure, training, service, upgrades, renewal, consumables, and exit costs.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Integration: Not publicly available - checked 2026-09-04 - Exact FDA submission

    The exact public FDA decision material does not establish a complete integration contract. Confirm DICOM, worklist, identity, interfaces, exports, routing, audit behavior, and downtime locally.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Installation timeline: Not yet reviewed

7 sources - 3 history items

Source ledger

  1. FDA 510(k) decision material K221599: HS40 Diagnostic Ultrasound System

    U.S. Food and Drug Administration - Published 2022-08-22 - Accessed 2026-09-04

    Scope: identity, purpose, clinicalUse, modality, anatomy, intendedUsers, careSetting, workflowRole, input, output, limitations, evidenceSummary

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  4. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  5. Medicare Coverage Database

    Centers for Medicare & Medicaid Services - Accessed 2026-09-01

    Scope: coverage, codingContext

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. Samsung Healthcare USA: Security Advisory

    Boston Imaging (Samsung) - Accessed 2026-10-26

    Scope: security

Research history

  1. K221599 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    human reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K260673

LOGIQ Vita; LOGIQ Vita Pro; LOGIQ Vita Express; LOGIQ Vita Plus; LOGIQ Vita Power; LOGIQ S20; LOGIQ S20 Pro; LOGIQ S20 Express; LOGIQ S20 Plus; LOGIQ S20 Power

GE Medical Systems Ultrasound and Primary Care Diagnostics

Authorized purpose: LOGIQ Vita and S20 are general-purpose diagnostic ultrasound systems for fetal and obstetric, abdominal, pediatric, small-organ, cephalic, cardiac, peripheral-vascular, musculoskeletal, urologic, and intraoperative examinations by qualified physicians.

Modality
Ultrasound
Anatomy
Fetus; abdomen; pelvis; small organs; head; heart; peripheral vessels; musculoskeletal; and urologic organs
Decision
2026-03-24
FDA-cleared K253370

LOGIQ Totus

GE Medical Systems Ultrasound and Primary Care Diagnostics

Authorized purpose: LOGIQ Totus is a general-purpose diagnostic ultrasound system for the labeled fetal, obstetric, abdominal, pediatric, small-organ, cephalic, cardiac, vascular, musculoskeletal, and urologic applications.

Modality
Ultrasound
Anatomy
Fetus; abdomen; pelvis; small organs; head; heart; peripheral vessels; musculoskeletal; and urologic organs
Decision
2026-01-08
FDA-cleared K253366

LOGIQ Fortis

GE Medical Systems Ultrasound and Primary Care Diagnostics

Authorized purpose: LOGIQ Fortis is a general-purpose diagnostic ultrasound system for the labeled fetal, obstetric, abdominal, pediatric, small-organ, cephalic, cardiac, vascular, musculoskeletal, and urologic applications, including supported AI-assisted functions.

Modality
Ultrasound
Anatomy
Fetus; abdomen; pelvis; small organs; head; heart; peripheral vessels; musculoskeletal; and urologic organs
Decision
2026-01-07
FDA-cleared K260667

Alturion Series Diagnostic Ultrasound System

Philips Ultrasound, LLC

Authorized purpose: Alturion Series diagnostic ultrasound systems acquire and display ultrasound images and fluid-flow information for the labeled fetal, abdominal, cardiac, cephalic, obstetric, musculoskeletal, ophthalmic, urologic, vascular, small-organ, and lung examinations.

Modality
Ultrasound
Anatomy
Fetus; abdomen; pelvis; small organs; head; heart; peripheral vessels; musculoskeletal anatomy; ophthalmic; urologic organs; and lung
Decision
2026-06-29

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history